Patients with Type 2 Diabetes have worse outcomes secondary to COVID-19 disease
The COVID-19 pandemic has infected over 7 million people and been responsible for over 400,000 deaths worldwide. Although the infection rate appears to have stabilized in some parts of the world, a second COVID-19 wave is anticipated in the fall-winter of 2020. Moreover, many COVID-19 survivors left in the wake of this first pandemic wave may face a lifetime of sequelae. The COVID-19 pandemic disproportionately affects patients with diabetes. In particular, those with type 2 diabetes are highly susceptible to SARS-CoV-2-induced adverse outcomes and complications. The massive global type 2 diabetes burden and high COVID-19 infection rate is creating large and significantly vulnerable COVID-19 type 2 diabetes patient populations.
Comorbid conditions predispose to adverse outcomes in COVID-19. Unfortunately, most type 2 diabetes patients suffer from comorbidities, including obesity, hypertension, chronic inflammation,and vascular complications, i.e., diabetic kidney disease, diabetic neuropathy and cardiovascular disease. Thus, type 2 diabetes patients, through their comorbid conditions, are at an especially dangerous risk of serious COVID-19 and death. Our overarching objective is to establish the knowledge base needed to develop risk-assessment tools and inform management of COVID-19 type 2 diabetes patients for the current and future waves.